Skip to main content
Year archive

Alligator Bioscience — 2019 filings

All 51 regulatory filings released by Alligator Bioscience (ATORX) in 2019, sourced directly from the official regulator.

51 Filings
2019 Period
2019 filings (51)
Filing Released Lang
Alligator Bioscience: Första patienten doserad med ATOR-1017 som utvecklas för behandling av spridd cancer
Regulatory Filings
2019-12-17 Swedish
Alligator Bioscience: First patient dosed with ATOR-1017 developed for metastasized cancer
Regulatory Filings
2019-12-17 English
Per-Olof Schrewelius lämnar rollen som CFO på Alligator Bioscience
Board/Management Information
2019-12-11 Swedish
CFO Per-Olof Schrewelius leaves Alligator Bioscience
Board/Management Information
2019-12-11 English
Major Shareholding Notification 2019
Major Shareholding Notification
2019-12-09 English
Alligator Bioscience AB utser Chief Operating Officer
Board/Management Information
2019-11-29 Swedish
Alligator Bioscience AB appoints Chief Operating Officer
Board/Management Information
2019-11-29 English
Valberedning utsedd inför årsstämma 2020 i Alligator Bioscience AB
AGM Information
2019-11-13 Swedish
Nomination Committee appointed in respect of AGM 2020 in Alligator Bioscience AB
Governance Information
2019-11-13 English
Aptevo Therapeutics och Alligator Bioscience presenterar nya prekliniska data för ALG.APV-527 på SITC 2019
Regulatory Filings
2019-11-08 Swedish
Aptevo Therapeutics and Alligator Bioscience present new preclinical data for ALG.APV-527 at the Society for Immunotherapy of Cancer 2019 Annual Meeting
Regulatory Filings
2019-11-08 English
Alligator Bioscience: ATOR-1017 skapar långvarig immunitet – nya prekliniska data presenteras på SITC 34th Annual Meeting
Regulatory Filings
2019-11-06 Swedish
Alligator Bioscience: ATOR-1017 Induces Long-Lasting Immunity – New Preclinical Data to be presented at SITC 34th Annual Meeting
Regulatory Filings
2019-11-06 English
Interim / Quarterly Report 2019
Interim / Quarterly Report 9M 2019
2019-10-24 Swedish
Interim / Quarterly Report 2019
Interim / Quarterly Report 9M 2019
2019-10-24 English
Alligator Bioscience signs antibody agreement for Greater China with Biotheus Inc.
Regulatory Filings
2019-08-20 English
Alligator Bioscience tecknar antikroppsavtal med Biotheus Inc. i Kina
Regulatory Filings
2019-08-20 Swedish
Alligator Bioscience återtar de globala rättigheterna för CD40-antikroppen ADC-1013 (JNJ-64457107) från Janssen
Regulatory Filings
2019-07-31 Swedish
Alligator Bioscience regains global rights from Janssen to CD40 agonistic antibody, ADC-1013 (JNJ-64457107)
Regulatory Filings
2019-07-31 English
Interim / Quarterly Report 2019
Interim / Quarterly Report Q2 2019
2019-07-11 Swedish
Interim / Quarterly Report 2019
Interim / Quarterly Report H1 2019
2019-07-11 English
Alligator Bioscience submits clinical trial application for ATOR-1017
Regulatory Filings
2019-06-18 English
Alligator Bioscience ansöker om att starta klinisk prövning för ATOR-1017
Regulatory Filings
2019-06-18 Swedish
Alligator Bioscience presenterar klinisk studiedesign för ATOR-1015 på ASCO
Regulatory Filings
2019-05-16 Swedish
Alligator Bioscience to present the ATOR-1015 Phase I study outline at ASCO
Regulatory Filings
2019-05-16 English
Alligator Bioscience: ADC-1013 clinical Phase I data to be presented at ASCO
Regulatory Filings
2019-05-15 English
Alligator Bioscience: Klinisk fas I-data för ADC-1013 presenteras på ASCO
Regulatory Filings
2019-05-15 Swedish
Kommuniké från årsstämma den 9 maj 2019 i Alligator Bioscience AB (publ)
AGM Information
2019-05-09 Swedish
Bulletin from the Annual Shareholders’ Meeting in Alligator Bioscience AB (publ) on May 9, 2019
AGM Information
2019-05-09 English
The Nomination Committee’s proposal for the annual shareholders’ meeting in Alligator Bioscience AB (publ)
AGM Information
2019-04-17 English
Valberedningens förslag inför årsstämman i Alligator Bioscience AB (publ)
AGM Information
2019-04-17 Swedish
Interim / Quarterly Report 2019
Interim / Quarterly Report Q1 2019
2019-04-17 Swedish
Interim / Quarterly Report 2019
Interim / Quarterly Report Q1 2019
2019-04-17 English
Alligator Bioscience: Preclinical data on the tumor-localizing anti-CTLA-4 antibody ATOR-1015 published in the Journal for ImmunoTherapy of Cancer
Regulatory Filings
2019-04-11 English
Alligator Bioscience: Prekliniska data för den tumörlokaliserande CTLA-4-antikroppen ATOR-1015 publicerade i Journal for ImmunoTherapy of Cancer
Regulatory Filings
2019-04-11 Swedish
Notice of annual shareholders’ meeting in Alligator Bioscience AB (publ)
AGM Information
2019-04-10 English
Kallelse till årsstämma i Alligator Bioscience AB (publ)
AGM Information
2019-04-10 Swedish
Alligator Bioscience: Nya prekliniska data för ATOR-1144 visar potential för aktivering av såväl det medfödda som det förvärvade immunsystemet samt direkt anti-tumöreffekt
Regulatory Filings
2019-04-02 Swedish
Alligator Bioscience: New preclinical data for ATOR-1144 demonstrate potential for activation of both the innate and the adaptive immune system, as well as direct anti-tumor effects
Regulatory Filings
2019-04-02 English
Annual Report 2018
Annual Report FY 2018
2019-03-22 English
Annual Report 2018
Annual Report FY 2018
2019-03-22 Swedish
Alligator Bioscience: New preclinical data demonstrate strong anti-tumor effects for the 4-1BB antibody ATOR-1017
Regulatory Filings
2019-03-18 English
Alligator Bioscience: Nya prekliniska data visar att 4-1BB-antikroppen ATOR-1017 ger kraftfulla anti-tumöreffekter
Regulatory Filings
2019-03-18 Swedish
Alligator Bioscience: Första patienten doserad i ATOR-1015 klinisk fas I-studie
Regulatory Filings
2019-03-07 Swedish
Alligator Bioscience: First Patient Dosed in Phase I study of ATOR-1015
Regulatory Filings
2019-03-07 English
Earnings Release 2018
Earnings Release FY 2018
2019-02-14 Swedish
Audit Report / Information 2018
Audit Report / Information FY 2018
2019-02-14 English
Alligator Bioscience publishes clinical phase I data for ADC-1013 in the International Journal of Cancer
Regulatory Filings
2019-01-29 English
Alligator Bioscience publicerar klinisk fas I-data för ADC-1013 i International Journal of Cancer
Regulatory Filings
2019-01-29 Swedish
Alligator Bioscience launches RUBY™, a novel concept in bispecific antibody formats
Regulatory Filings
2019-01-07 English
Alligator Bioscience lanserar RUBY™, ett nytt formatkoncept för bispecifika antikroppar
Regulatory Filings
2019-01-07 Swedish